公开(公告)号：US20240365660A1

公开(公告)日：2024-10-31

申请号：US18579875

申请日：2022-12-08

Applicant: LG CHEM, LTD.

Inventor： Miyeon HAN ,  Dong Hoon LEE ,  Min Woo JUNG ,  Seulchan PARK ,  Hoon Jun KIM ,  Hye Min CHO ,  Hojung LEE

IPC: H10K85/60 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D409/14 ,  C07F7/08 ,  C09K11/06 ,  H10K50/11 ,  H10K85/40

CPC classification number: H10K85/654 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D409/14 ,  C07F7/0812 ,  C09K11/06 ,  H10K85/40 ,  H10K85/615 ,  H10K85/622 ,  H10K85/626 ,  H10K85/6574 ,  H10K85/6576 ,  C09K2211/1018 ,  H10K50/11

Abstract: Provided is a novel compound of Chemical Formula 1:




wherein in Chemical Formula 1: n is an integer of 1 to 6; X is O or S; L1 and L2 are each independently a single bond, substituted or unsubstituted C6-60 arylene, or substituted or unsubstituted C2-60 heteroarylene containing at least one heteroatom selected from the group consisting of O, S, Si, P and B; Ar1 is cyano, substituted or unsubstituted C6-60 aryl, or substituted or unsubstituted C2-60 heteroaryl containing at least one heteroatom selected from the group consisting of O, S, Si, P and B; and Ar2 and Ar3 are each independently substituted or unsubstituted C6-60 aryl, or substituted or unsubstituted C2-60 heteroaryl containing at least one heteroatom selected from the group consisting of O, S, Si, P and B; and an organic light emitting device including the same.

公开(公告)号：US20240360121A1

公开(公告)日：2024-10-31

申请号：US18597265

申请日：2024-03-06

Applicant: Board of Regents, The University of Texas System

Inventor： Maria Emilia DI FRANCESCO ,  Philip JONES ,  Timothy HEFFERNAN ,  Matthew M. HAMILTON ,  Zhijun KANG ,  Michael J. SOTH ,  Jason P. BURKE ,  Kang LE ,  Christopher Lawrence CARROLL ,  Wylie S. PALMER ,  Richard LEWIS ,  Timothy MCAFOOS ,  Barbara CZAKO ,  Gang LIU ,  Jay THEROFF ,  Zachary HERRERA ,  Anne YAU

IPC: C07D417/14 ,  A61K31/4192 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/454 ,  A61K31/497 ,  A61K31/501 ,  A61K45/06 ,  C07D401/14 ,  C07D403/06 ,  C07D403/14 ,  C07D405/14 ,  C07D417/06 ,  C07D493/08

CPC classification number: C07D417/14 ,  A61K31/4192 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/454 ,  A61K31/497 ,  A61K31/501 ,  A61K45/06 ,  C07D401/14 ,  C07D403/06 ,  C07D403/14 ,  C07D405/14 ,  C07D417/06 ,  C07D493/08

Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I:




Methods of inhibition GLS1 activity in a human or animal subject are also provided.

公开(公告)号：US20240360103A1

公开(公告)日：2024-10-31

申请号：US18573634

申请日：2022-06-30

Applicant: Apellis Pharmaceuticals, Inc.

Inventor： Johannes Wilhelm Georg Meissner ,  Andrew Simon Cook ,  Mark William Orme

IPC: C07D401/14 ,  A61K31/496 ,  A61K31/501 ,  A61K31/506 ,  C07D403/06 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14

CPC classification number: C07D401/14 ,  A61K31/496 ,  A61K31/501 ,  A61K31/506 ,  C07D403/06 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14

Abstract: Among other things, the present disclosure provides technologies for modulating complement activation. In some embodiments, the present disclosure provides compounds that inhibit C3 convertase activity. In some embodiments, the present disclosure provides methods for treating complement-mediated conditions, disorders or diseases. In some embodiments, the present disclosure provides methods for treating conditions, disorders or diseases mediated by C3 convertase.

公开(公告)号：US20240360082A1

公开(公告)日：2024-10-31

申请号：US18291083

申请日：2022-07-22

Applicant: NOVARTIS AG

Inventor： Graham Charles BLOOMFIELD ,  Matthew James HESSE ,  Richard Yichong HUANG ,  Michael Robert MASER ,  James Clifford SUTTON ,  Benjamin Robert TAFT ,  David Charles TULLY

IPC: C07D213/82 ,  A61K31/4418 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/498 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/553 ,  C07D401/10 ,  C07D401/12 ,  C07D405/10 ,  C07D405/14 ,  C07D409/12 ,  C07D413/10 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04 ,  C07D491/052 ,  C07D493/08 ,  C07D493/10 ,  C07D498/04 ,  C07D498/08 ,  C07D498/10

CPC classification number: C07D213/82 ,  A61K31/4418 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/498 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/553 ,  C07D401/10 ,  C07D401/12 ,  C07D405/10 ,  C07D405/14 ,  C07D409/12 ,  C07D413/10 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04 ,  C07D491/052 ,  C07D493/08 ,  C07D493/10 ,  C07D498/04 ,  C07D498/08 ,  C07D498/10

Abstract: The disclosure provides compounds of Formula (I): (I) as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certain viral disorders, including influenza.

公开(公告)号：US20240351984A1

公开(公告)日：2024-10-24

申请号：US18735162

申请日：2024-06-05

Applicant: Volastra Therapeutics, Inc.

Inventor： Derek A. COGAN

IPC: C07D209/96 ,  A61P35/00 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/06 ,  C07D403/12 ,  C07D403/14 ,  C07D405/06 ,  C07D405/12 ,  C07D405/14 ,  C07D409/06 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D491/107 ,  C07D491/113 ,  C07F9/572

CPC classification number: C07D209/96 ,  A61P35/00 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/06 ,  C07D403/12 ,  C07D403/14 ,  C07D405/06 ,  C07D405/12 ,  C07D405/14 ,  C07D409/06 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D491/107 ,  C07D491/113 ,  C07F9/5728

Abstract: The present disclosure relates generally to inhibitors of KIF18A, compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to indoline inhibitors of KIF18A and methods of their use for treating disease mediated by KIF18A, such as cancer.

公开(公告)号：US12127474B2

公开(公告)日：2024-10-22

申请号：US16973867

申请日：2019-02-26

Applicant: SAMSUNG SDI CO., LTD. ,  SAMSUNG ELECTRONICS CO., LTD.

Inventor： Jun Seok Kim ,  Jinhyun Lui ,  Dong Min Kang ,  Jongwoo Won ,  Byoungkwan Lee ,  Sangshin Lee ,  Jihun Shin ,  Jinseok Jang ,  Sung-Hyun Jung

IPC: H01L51/50 ,  C07D209/88 ,  C07D251/24 ,  C07D405/04 ,  C07D405/14 ,  C07D495/04 ,  C09K11/06 ,  H10K85/60 ,  H10K50/11 ,  H10K50/15 ,  H10K101/10

CPC classification number: H10K85/636 ,  C07D209/88 ,  C07D251/24 ,  C07D405/04 ,  C07D405/14 ,  C07D495/04 ,  C09K11/06 ,  H10K85/615 ,  H10K85/622 ,  H10K85/633 ,  H10K85/654 ,  H10K85/657 ,  H10K85/6572 ,  H10K85/6574 ,  C09K2211/1018 ,  H10K50/11 ,  H10K50/15 ,  H10K2101/10

Abstract: The present invention is related to a first compound for an organic optoelectronic device represented by Chemical Formula 1, a composition for an organic optoelectronic device including the same, an organic optoelectronic device, and a display device.
In Chemical Formula 1, definitions of each substituent are the same as defined in the specification.

公开(公告)号：US12122742B2

公开(公告)日：2024-10-22

申请号：US17423688

申请日：2020-01-16

Applicant: Rutgers, The State University of New Jersey

Inventor： Longqin Hu ,  Dhulfiqar A. Abed

IPC: C07C323/67 ,  C07C315/04 ,  C07D209/14 ,  C07D209/48 ,  C07D333/58 ,  C07D403/12 ,  C07D405/14 ,  C07D407/12

CPC classification number: C07C323/67 ,  C07C315/04 ,  C07D209/14 ,  C07D209/48 ,  C07D333/58 ,  C07D403/12 ,  C07D405/14 ,  C07D407/12

Abstract: This patent document discloses novel compounds and methods of preventing or treating diseases or conditions related to Keap1-Nrf2 interaction activity by use of the novel compounds. As direct inhibitors of Keap1-Nrf2 interaction, the compounds disclosed herein are more specific and free of various undesirable effects than existing indirect inhibitors, and are potential dmg candidates of chemopreventive and therapeutic agents for treatment of various diseases or conditions involving oxidative stress and/or inflammation, including but not limited to cancers, diabetes, Alzheimer's, Parkinson's, and inflammatory bowel disease including ulcerative colitis.

公开(公告)号：US20240343715A1

公开(公告)日：2024-10-17

申请号：US18756237

申请日：2024-06-27

Applicant: Zhejiang Brilliant Optoelectronic Technology Co.,Ltd.

Inventor： Jiahui TAN ,  Hao ZHANG ,  Junyou PAN

IPC: C07D405/14 ,  C07D409/14 ,  C09K11/06 ,  H10K85/60 ,  H10K101/30

CPC classification number: C07D405/14 ,  C07D409/14 ,  C09K11/06 ,  H10K85/654 ,  H10K85/6572 ,  H10K85/6574 ,  H10K85/6576 ,  H10K2101/30

Abstract: Disclosed are organic compounds including a structure of formula (I). Also provided are mixtures containing a first organic compound (H1) and a second organic compound (H2), the first organic compound (H1) includes at least one of the organic compound. Further provided are organic electronic devices containing the organic compounds or the mixtures. By means of device structure optimization, improved device performance can be achieved, specifically, a high-performance OLED device can be implemented, improved material and manufacturing technical options are provided for full-color display and lighting applications.

公开(公告)号：US20240336594A1

公开(公告)日：2024-10-10

申请号：US18576708

申请日：2022-06-24

Applicant: BETTA PHARMACEUTICALS CO., LTD

Inventor： Bang FU ,  Yinlong LI ,  Wei REN ,  Qichao SHEN ,  Guolong DU ,  Xiaojun ZHOU ,  Yun SUN ,  Yuzhen ZHOU ,  Xiao SUN ,  Weidong CAI ,  Xiangyong LIU ,  Lieming DING ,  Jiabing WANG

IPC: C07D401/14 ,  A61K31/167 ,  A61K31/18 ,  A61K31/423 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/501 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/519 ,  A61K31/538 ,  C07C237/40 ,  C07C311/32 ,  C07C317/32 ,  C07C323/33 ,  C07D205/12 ,  C07D213/56 ,  C07D263/56 ,  C07D265/36 ,  C07D401/04 ,  C07D401/06 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08 ,  C07D491/048 ,  C07D491/107

CPC classification number: C07D401/14 ,  A61K31/167 ,  A61K31/18 ,  A61K31/423 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/501 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/519 ,  A61K31/538 ,  C07C237/40 ,  C07C311/32 ,  C07C317/32 ,  C07C323/33 ,  C07D205/12 ,  C07D213/56 ,  C07D263/56 ,  C07D265/36 ,  C07D401/04 ,  C07D401/06 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08 ,  C07D491/048 ,  C07D491/107

Abstract: A compound of formula I and a use thereof as an MALT1 inhibitor, and a pharmaceutical composition containing the compound. The compound can be used to treat diseases or disorders such as cancer.

公开(公告)号：US20240334822A1

公开(公告)日：2024-10-03

申请号：US18732952

申请日：2024-06-04

Applicant: SAMSUNG SDI CO., LTD.

Inventor： Yongtak YANG ,  Dong Min KANG ,  Hyung Sun KIM ,  Jinhyun LUI ,  Seungin PARK ,  Jaejin OH ,  Sung-Hyun JUNG ,  Ho Kuk JUNG ,  Youngkyoung JO ,  Pyeongseok CHO ,  Dalho HUH

IPC: H10K85/60 ,  C07D403/10 ,  C07D403/14 ,  C07D405/14 ,  C07D487/04 ,  C07F15/00 ,  C09K11/06 ,  H10K50/11 ,  H10K85/30 ,  H10K101/10

CPC classification number: H10K85/654 ,  C07D403/10 ,  C07D403/14 ,  C07D405/14 ,  C07D487/04 ,  C07F15/0033 ,  C07F15/0086 ,  C09K11/06 ,  H10K85/342 ,  H10K85/346 ,  H10K85/6572 ,  H10K85/6574 ,  C09K2211/1029 ,  C09K2211/1044 ,  C09K2211/185 ,  H10K50/11 ,  H10K2101/10

Abstract: A composition for an organic optoelectronic device, an organic optoelectronic device, and a display device, the composition including a first compound; a second compound; and a third compound, the first compound, the second compound, and the third compound are different from each other, the first compound is represented by Chemical Formula I, the second compound is represented by Chemical Formula II or Chemical Formula III, and the third compound is represented by Chemical Formula II or Chemical Formula III,